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Abstract— Immunisation against M. tuberculosis with current 
available BCG vaccine lacks efficacy in preventing adult 
pulmonary tuberculosis. Targeting nasal mucosa is an attractive 
option for a more effective immunization. The delivery of BCG 
via the intranasal route involves overcoming barriers such as 
crossing the physical barrier imposed by the mucus layer and 
ciliar remotion, cellular uptake and intracellular trafficking by 
antigen presenting cells. Due to its biodegradable, immunogenic 
and mucoadhesive properties, chitosan particulate delivery 
systems can act both as vaccine carrier and adjuvant, improving 
the elicited immune response. In this study, different 
combinations of Chitosan/Alginate/TPP microparticles with BCG 
were produced as vaccine systems. The developed microparticle
system successfully modulates BCG surface physicochemical 
properties and promotes effective intracellular uptake by human 
macrophage cell lines Preliminary immune responses were 
evaluated after s.c. and intranasal immunisation of BALB/c mice.
BCG vaccination successfully stimulated the segregation of IgG2a 
and IgG1, where intranasal immunisation with chitosan/alginate 
particulate system efficiently elicited a more equilibrated
cellular/humoral immune response.
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I. INTRODUCTION
Tuberculosis remains an important cause of morbidity and
mortality worldwide. [1] The current vaccine, Mycobacterium
bovis bacillus Calmette-Guérin (BCG), has variable protective
efficacy ranging from 0 to 85% in different studies [2], hence,
efforts are being made in order to develop an improved 
vaccine. As for many pathogens, M. tuberculosis infection 
occurs through mucosa. Therefore, the development of an 
efficient vaccine will require an appropriate antigen 
presentation and adjuvant effect that can induce both mucosal 
and systemic immune response, preventing not only infectious 
disease but also colonization of mucosal surfaces [3].
Biodegradable particulate delivery systems have been 
successfully used in recent vaccine development, and mucosal 
delivery systems designed to enhance the immune response 
following mucosal immunization have been evaluated for 
efficacy in tuberculosis vaccines [4-5]. However, to our 
knowledge, none using live viable vaccines. 
Live vaccines, such as BCG, provide several important 
advantages over other strategies, as they act like the natural 
infection, being readily uptaken by specialized antigen 
presenting cells, thus, inducing strong humoral and cellular 
immune responses.
As a nasal carrier system, chitosan microparticles are ideal, 
due to their mucoadhesive and adjuvant properties, and ability 
to act as antigen depot, enabling a better interaction between 
the carried vaccine and the membrane epithelium, thus,
allowing a more efficient uptake by alveolar macrophages [6].
Through modification of particle features, such as size, zeta 
potential and composition, a different pattern of MHC 
presentation and acquired immunity can be obtained, thus, 
tuning and improving the immune response [7-9]. 
II. GOALS
A particle-mediated delivery system of chitosan and 
alginate was designed via a mild ionotropic gelation procedure 
with sodium tripolyphosphate (TPP), as previously described 
[10], for efficient encapsulation of live attenuated BCG.
Physico-chemical characterization of particulate delivery 
system and assessment of intracellular uptake by macrophages 
were performed.
The titres of IgG2a and IgG1 were investigated using a 
purified protein derivative (PPD) bovine tuberculin, probed 
with serum samples collected at biweekly intervals from 
BALB/c mice, following vaccination with different BCG 
microparticle formulations, both intranasal (i.n.) and 
subcutaneously (s.c.) administrated.
III. MATERIALS AND METHODS
A. Materials
Chitosan of different molecular weight (low molecular 
weight (CH-LMW, 150 kDa), medium molecular weight (CH-
MMW, 450 kDa), and high molecular weight (CH-HMW, 600 
kDa)), sodium alginate with different viscosities, and TPP were 
obtained from Sigma Aldrich, UK.
Both BCG strains used in this study - M. bovis BCG 
Pasteur (ATCC35734) and a recombinant M. bovis BCG 
harbouring a pMN437 plasmid [11], were kindly supplied by 
Prof Elsa Anes (FFUL). All cell culture reagents were from 
Invitrogen, UK.
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